Recent evidences suggest that MET is able to i) modulate anabolic metabolism, inducing cell cycle arrest and cell death [13, 33]; ii) reduce GSC cells, increasing the treatment sensitivity [22] and iii) improve responsiveness of glioma cells to TMZ treatment, counteracting the MGMT presence [13]. The gene discussed is MGMT; the disease is glioma.